AXSMAxsome Therapeutics, Inc.
- GlobeNewswire
Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Total 2Q 2026 net product revenue of $218.4 million, representing 46% year-over-year growth AUVELITY® 2Q 2026 net product sales of $180.3 million, representing 51% year-over-year growth SUNOSI® 2Q 2026 net product ...
- Analyst Upgrades
Mizuho Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $306
Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics with a Outperform and lowers the price target from $310 to $306. ...
- Analyst Upgrades
This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday
Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, with positive outlooks and raised price targets. ...
- Analyst Upgrades
BMO Capital Initiates Coverage On Axsome Therapeutics with Outperform Rating, Announces Price Target of $310
BMO Capital analyst Malcolm Hoffman initiates coverage on Axsome Therapeutics with a Outperform rating and announces Price Target of $310. ...
- Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $290 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics with a Buy and maintains $290 price target. ...
- GlobeNewswire
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
FDA sets PDUFA target action date of May 1, 2027 NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...
- GlobeNewswire
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will ...
- Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $290 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics with a Buy and maintains $290 price target. ...
- Analyst Upgrades
RBC Capital Maintains Outperform on Axsome Therapeutics, Raises Price Target to $304
RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics with a Outperform and raises the price target from $302 to $304. ...
- GlobeNewswire
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHD NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company ...
- GlobeNewswire
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the ...
- GlobeNewswire
Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is ...
- Analyst Upgrades
TD Cowen Maintains Buy on Axsome Therapeutics, Raises Price Target to $300
TD Cowen analyst Joseph Thome maintains Axsome Therapeutics with a Buy and raises the price target from $275 to $300. ...
- GlobeNewswire
Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced ...
- GlobeNewswire
Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced ...
- GlobeNewswire
Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced ...
- GlobeNewswire
Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month
NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today highlighted its ...
- GlobeNewswire
Axsome Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will ...
- GlobeNewswire
Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced ...
- GlobeNewswire
Axsome Therapeutics Recognizes Mental Health Month
NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced its support ...
- Analyst Upgrades
Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $242
Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics with a Equal-Weight and raises the price target from $217 to $242. ...
- Analyst Upgrades
RBC Capital Maintains Outperform on Axsome Therapeutics, Raises Price Target to $302
RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics with a Outperform and raises the price target from $242 to $302. ...
- Analyst Upgrades
Wells Fargo Maintains Overweight on Axsome Therapeutics, Raises Price Target to $255
Wells Fargo analyst Benjamin Burnett maintains Axsome Therapeutics with a Overweight and raises the price target from $225 to $255. ...
- Analyst Upgrades
Guggenheim Maintains Buy on Axsome Therapeutics, Raises Price Target to $260
Guggenheim analyst Yatin Suneja maintains Axsome Therapeutics with a Buy and raises the price target from $245 to $260. ...
- Analyst Upgrades
Mizuho Maintains Outperform on Axsome Therapeutics, Raises Price Target to $310
Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics with a Outperform and raises the price target from $228 to $310. ...